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Therapeutic Potential of Baicalein 
in Parkinson’s Disease: Focus 
on Inhibition of α-Synuclein 
Oligomerization and Aggregation
Hayate Javed and Shreesh Ojha
Abstract
Parkinson’s disease (PD) is the most common neurodegenerative diseases, 
which affects the people in old age. The neuropathological symptoms of PD include 
the degeneration of dopaminergic neurons in the substantia nigra pars compacta, 
and presence of intracellular inclusions of α-synuclein (α-syn) aggregates. α-Syn, 
a natively unfolded protein, has been found to play a key role in PD pathology. 
Several mechanistic studies revealed the numerous aspects of α-syn fibrillation 
and aggregation process that lead to dopaminergic neurodegeneration in PD. Till 
to date, there is no complete cure of PD, but some therapeutic agents are able to 
halt the disease progression. Scutellaria baicalensis Georgi is a traditional Chinese 
medicine commonly used to treat the central nervous system diseases. Recently, it 
has been confirmed that root of S. baicalensis Georgi contains baicalein (5,6,7-trihy-
droxyflavone) as a major bioactive flavone constituent. Baicalein possess numerous 
pharmacological properties such as antiaggregation of amyloid proteins including 
α-syn, antioxidant, anti-inflammatory, and antiapoptotic. In the light of these 
properties, baicalein has potential therapeutic efficacy for PD. In this chapter, we 
explored the pharmacological protective actions of baicalein against α-syn fibrilla-
tion and aggregation that make it suitable for PD treatment and also discussed the 
possible mechanisms underlying the effects.
Keywords: Parkinson’s disease, α-Synuclein, baicalein, flavonoids, dopaminergic 
neurons
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
involving movement disorders [1, 2]. Worldwide, about 10 million people are 
living with PD and it affects 3–4% of individuals over the age of 65 years [3, 4]. 
Symptomatically, PD is characterized by the movement and behavioral disorders 
and pathologically characterized by the deterioration of dopaminergic neurons in 
the substantia nigra and the presence of Lewy bodies [5, 6]. The diagnosis of PD, in 
general, includes motor disorders such as bradykinesia, cogwheel rigidity, resting 
tremors, postural instability, and slowness or absence of voluntary movements 
along with neuropsychiatric manifestations [7, 8]. The Lewy bodies in PD result 
from accumulation of intracellular α-synuclein (α-syn) inclusions in neurons, 
Synucleins - Biochemistry and Role in Diseases
2
and aggregates of α-syn spread through the brain following a specific pattern [9]. 
The neuron-to-neuron transfer of α-syn is considered critical for the propagation 
of Lewy body pathology. The definitive postmortem diagnosis and pathological 
character of PD constitute the presence of aggregated (i.e., fibrillar, spherical, and 
oligomeric) forms of α-syn protein in the soma and processes including axons and 
dendrites of affected neurons. The familial form of PD is caused by mutations in the 
SNCA gene, which is the first determinant of PD [10]. Moreover, inherited forms 
of PD result from the genetic overexpression via gene duplication or triplication 
[11, 12]. Importantly, more α-syn gene copies result in highly aggressive form of 
the disease, which suggests a direct relationship between disease severity and the 
expression level of α-syn [13]. The fibrillated form of α-syn protein is the abundant 
component of Lewy bodies, which are the pathological hallmarks of sporadic form 
of PD and present as cytoplasmic inclusions [14]. Consequently, α-syn is believed to 
play a crucial and significant causative role in most, if not all, forms of PD.
In the last 30 years, the approach in the treatment of PD is based on enhancing 
the deteriorating levels of dopamine neurotransmitter through administering dopa-
mine precursor l-dopa. Until now, the replacement of dopamine by l-dopa admin-
istration is the standard treatment for PD management [15]. However, l-dopa 
appears to provide only symptomatic relief in correcting the motor abnormalities 
and did not inhibit or reverse the PD progression [16]. However, the long-term 
use of dopamine precursor drugs found to produce numerous adverse effects and 
induce complications that ultimately flop to treat PD patients if disease progresses 
[17]. Thus, there is a great requirement to develop new drugs for the management 
of PD, which are not only therapeutic but can also prevent the initiation or delay or 
stop the progression of the disease.
In the past few years, there is an enormous emphasis on the medicinal use of 
plant extracts, which are also reputed for their therapeutic claims in a variety of 
traditional medicines. The traditional preparations usually contain many medicinal 
plant extracts that have been shown better therapeutic efficacy on neurological 
diseases, such as cerebral stroke, dementia, and paralysis, in clinical setup for 
decades [18, 19]. Though all these herbs-based medicinal preparations are used in 
the traditional practice of medicine with perceived safety and efficacy, the precise 
pharmacological and molecular mechanisms involved in the therapeutic efficacy 
of these traditional Chinese medicines remain unclear. Majority of the mechanisms 
purported behind the clinical efficacy of these herbal medicines are based on 
generalized antioxidant and anti-inflammatory property, rather a well-established 
pharmacological target. They are therefore not well accepted in modern medicine, 
which is based on rigorously documented evidence-based randomized clinical data. 
It is challenging to systematically identify these mechanisms with modern bio-
chemical and pharmacological techniques [20]. Simultaneously, medicinal plants 
are well acknowledged as a source of modern drugs, which provides a drug discov-
ery approach and further leads to drug development. It is well documented that 
enhanced dietary consumption of herbal medicines reduces the risk of developing 
neurodegenerative diseases [21].
In an approach to identify a novel molecule form of traditional medicine, 
the root of Scutellaria baicalensis Georgi garnered enormous attention in drug 
discovery for neurodegenerative diseases. Scutellaria baicalensis Georgi, widely 
grown in Mongolia, Korea, Siberia, China, Japan, and the Russian Far East, 
represents one of the important ingredients in the decoction of traditional herbal 
preparation employed for the treatment of CNS diseases [21]. Pharmacokinetic 
study confirmed that baicalein, a flavone chemically known as 5,6,7-trihydroxy-
flavone, is one of the prominent bioactive components of the roots of Scutellaria 
baicalensis Georgi [22]. Baicalein is one of the widely studied compounds and 
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reputed for its multiple pharmacological actions including antibacterial, anti-
viral, anticarcinogenic, and anti-inflammatory activities in traditional Chinese 
medicine [23–26]. Baicalein has a wide safety of margin and appears to be able to 
cross the blood-brain barrier [27]. Several studies based on animal model of AD 
and PD have shown that baicalein exhibits neuroprotective properties [26–29]. 
Therefore, baicalein has been the central molecule to investigate its versatility as 
therapeutic agent for neurological diseases [21]. In this chapter, we will describe 
the therapeutic importance of baicalein against the PD with a focus in the ame-
lioration of α-syn, which is central protein in the pathogenesis of PD. In addi-
tion, we will also highlight the potential underlying biochemical mechanisms of 
action of baicalein (Figure 1).
2. α-Syn a major mediator in PD pathogenesis
α-Syn is a 140 amino acid protein, which is encoded by SNCA gene located on 
human chromosome 4 and most abundantly expressed in presynaptic terminals and 
helps in the maintenance of neurotransmitter systems in CNS [28]. Regardless of its 
abundant distribution in numerous areas intricated in multifaceted activities, α-syn 
pathology exists in selectively vulnerable areas rather than its site of expression in 
the brain [28, 29]. Furthermore, red blood cells are also abundant in α-syn [30] and 
many other CNS tissues [31, 32], which indicates broader range of α-syn functions 
throughout the body. Almost two decades have been spent to find out the exact 
role of α-syn physiology; its mechanism of action is still unknown, and complex 
dynamics of this protein is characterized by its ability to achieve the toxic effect as 
well as flexibility to adapt. α-Syn has gained much consideration as important factor 
in PD pathophysiology. α-Syn exists in a dynamic equilibrium from monomeric to 
oligomeric states, and this equilibrium prevents formation of fibrils in physiologi-
cal conditions. Importantly, multifunctional properties of α-syn are predicted by 
its structure that has been attributed to this protein [33]. The structure flexibility 
property of α-syn allows it to accept a wide range of conformations depending on 
binding partners and environment [34, 35]. Because of its abundant presence at 
presynaptic terminals, chaperone function of α-syn is the key cellular function, 
which controls the exocytosis through trafficking and organizing the synaptic 
vesicle pool. Mutations in α-syn coding gene SNCA lead to functional changes of 
SNAP REceptor (SNARE) protein, which is a receptors family that binds soluble 
N-ethylmaleimide sensitive fusion attachment proteins (SNAP) receptor (SNARE) 
proteins and controls its assembly [36]. Moreover, α-syn also targets presynaptically 
dopamine active transporter (DAT) [37].
Several approaches occur to prevent the oligomerization of α-syn [39], 
which includes hydrophobic interactions between C- and N-terminals of α-syn 
[40]. Interestingly, α-syn exhibits a polar C-terminal tail, which can bind to 
Figure 1. 
The chemical structure of baicalein.
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hydrophobic region of other denatured protein, having functional and structural 
homology with different molecular chaperones. Therefore, the flexibility of α-syn 
depends on the capacity of this protein to autoassemble and function as intramo-
lecular chaperone [41]. Autochaperone property was found absent in C-terminus 
of truncated α-syn and that will increase the formation of α-syn aggregates 
compared with the full-length α-syn [39]. At present, the exact biological func-
tions of α-syn are unknown; but there is a substantial amount of ongoing research 
that helps us to understand this gap in our knowledge. The functional repertoire 
of α-syn is largely studied through determining the irregularities following 
overexpression, expression of mutant forms of α-syn, or loss of expression. 
The number of studies indicates α-syn involved in the formation of synaptic 
vesicles, mitochondrial function, and/or dopamine synthesis and metabolism. 
Furthermost characteristics strongly argue for important role in synaptic plastic-
ity and neurotransmitter release. Chaperone plays an important role in the folding 
of polypeptide during proteins translation, and assembly misfolding is common 
with aging yet they are generally partial by numerous quality control machineries 
that degrade the misfolded and denatured proteins [42]. With the complex orga-
nization of α-syn expression and its function of great adaptability, homeostatic 
functions failures do not bring to uneven function gain, instead trigger a sequence 
of neurodegenerative process in the intracellular system.
Several studies conducted in PD patients and animal models support the idea 
that the proteostasis of α-syn has a critical role in the PD pathogenesis. This concept 
backs to two decades when two discoveries provided the evidence that PD is linked 
to α-syn mutations. The first report published by Polymeropoulos and colleague 
for the identification of a missense mutation in α-syn gene causing early onset of 
familial form of PD [9]. In the same year, an experimental report showed that Lewy 
bodies contain higher amount of α-syn that appears as intracytoplasmic inclusion 
of α-syn aggregates and considered as classical pathological hallmarks of PD [14]. 
Soon after these discoveries, the presence of Lewy body in the brain parenchyma 
of sporadic idiopathic forms of PD was also found [43]. To examine the prob-
able causal links, pathological and physiological functions of α-syn and different 
misfolding proteins have been investigated in relative with documented features of 
PD. Several risk factors for PD have been explored that are genetic and environmen-
tal. Point mutations, mitochondrial dysfunctions, oxidative stress, neuroinflamma-
tion, multiplications, and specific polymorphisms are the genetic causes that may 
lead to develop suitable environment for progressing PD. Remarkably, these factors 
are equally responsible to exert α-syn toxicity. Despite having good quality control 
structures to confirm a precise α-syn assembly and the capability to control α-syn 
oligomerization, this protein also expresses its neurotoxic effects upon formation of 
oligomers from soluble monomers, and then gradually formed protofibrils to large 
α-syn aggregates which eventually leads to Lewy body formation [44]. A greater 
chance of α-syn aggregation is accessible by various posttranslational covalent 
modifications including conformational changes, which direct α-syn more vulner-
able to aggregation [35]. α-Syn truncation at the C-terminus and tyrosine nitration 
(Tyr125) are usually observed in α-syn aggregates and often found to enhance its 
in vitro fibrillation [45]. Additionally, aging diminishes the proteolytic efficiency 
that plays an important additive role in the accumulation of α-syn. These finding 
supporting the data showing enhanced α-syn levels in nigral neurons in aged brain. 
In the normal brain, intracellular homeostasis of α-syn is confirmed by the accumu-
lative functions of lysosomal autophagy, and ubiquitin-proteasome systems with 
the previous one play a key role in the clearance of oligomeric α-syn. Irregularities 
in both systems lead to excessive production and accumulation of α-syn that even-
tually end up to formation of α-syn aggregates.
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3.  Abnormal accumulation of α-syn causes dopaminergic 
neurodegeneration
In PD, decreased striatal dopamine occurred following selective neurode-
generation of dopaminergic neurons of the substantia nigra par compacta (SNc) 
and impairment of several basal ganglia functions. It is still unknown through 
which mechanism α-syn causes dopaminergic neurons vulnerable and it needs 
to be fully elucidated. α-Syn is associated to dopamine neurons for its capability 
to control homeostasis of dopamine in the synapses and effects DAT activ-
ity, but the exact mechanism is still debatable [46]. α-Syn plays a key role as a 
modulator for dopamine synthesis and metabolism by decreasing the tyrosine 
hydroxylase phosphorylation and stabilizes in inactive state [47]. Therefore, 
α-syn absence employs considerable effect on dopaminergic systems because it 
reduces dopamine levels in the striatum and decreased DAT functions. Absence 
of α-syn is also linked with reduced striatal dopamine uptake, decreased number 
of TH-positive nigral dopaminergic neurons, and nerve terminals in the striatum 
[48]. However, the sensitivity of dopaminergic neurons also conferred to intrin-
sic and excitotoxic insult and does not rely on absence of dopamine metabolism. 
There are two characteristic features of dopaminergic neurons which makes 
them especially more susceptible to excitotoxic challenge. First dopamine 
neurons show a prolonged axonal branch, which offer extensive neurotrans-
mitter release sites. Enhanced mitochondrial impairment is observed in the 
axons of dopaminergic neurons and this is one of the reasons to show elevated 
susceptibility. Second, dopamine neurons act as autonomous pacemakers and 
display spontaneous activity. The activity of dopaminergic neurons is considered 
through oscillations in intracellular calcium (Ca2+) levels, which is operated 
by voltage-dependent L-type Ca2+ channels opening to maintain a rhythmic 
(2–10 Hz) spiking [49]. This capability is connected to decreased intrinsic Ca2+ 
levels and required a strict quality control for Ca-mediated processes from 
intracellular reservoir, endorsing Ca2+ entry into the mitochondria and ATP 
production by oxidative phosphorylation [50]. All these processes are required 
to complete the requirements of bioenergetics and to prevent the unnecessary 
activation of ATP-sensitive potassium channels that may inhibit the spontane-
ous activity of neurons. Nigral dopaminergic neurons and different brain nuclei 
neurons involved in sensorimotor integration are capable with mechanisms that 
maintain to rapidly implement a correct strategy upon environmental stress. As a 
result, for this adaptive ability is the vulnerability of the system to environmen-
tal toxins, age, and genetic mutations or that can increase the reactive oxygen 
species production which ca warrant the proteostasis, DNA damages, especially 
in mitochondria. Impairment in mitochondria ultimately leads to cause impaired 
mitophagy and also compromised. Recently, Burbulla and colleagues [51] 
showed inactivation of DJ-1 causes additive toxic effect of elevated α-syn levels, 
mitochondrial dysfunction, and stimulation of dopaminergic receptors in mice. 
Remarkably, overexpression of human α-syn A53T [52] in dopaminergic neurons 
and constitutive DJ-1 deficiency in mice showed enhanced levels of oxidized 
dopamine in dopaminergic neurons and decreased lysosomal activity.
4. Baicalein as a potential molecule of natural origin to target α-syn
In the recent years, a growing effort has been taken in the development of inno-
vative neuroprotective molecules of natural origin with high efficacy and low side 
effects to prevent neuronal deaths [10, 19]. Several studies have been attempted to 
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examine the effects of extracted components from different plants on neurotoxicity. 
Among the numerous compounds from plants, flavonoids are the utmost effec-
tive components with a broader range of pharmacological and health-promoting 
properties [20, 21]. To date, almost 8000 different flavonoid compounds have been 
discovered and are classified into various subgroups, including flavonols, flavones, 
flavanols, flavanones, isoflavones, etc. [22]. Numerous vegetables and fruits, flavo-
noid compounds are the major classes of natural polyphenols. The consumption of 
flavonoid-rich fruits and vegetables significantly reduces the risk of many diseases 
in humans [23, 24].
Baicalein (5,6,7-trihydroxyflavone; C15H10O5) is an important flavonoid com-
pound mainly isolated from the roots of S. baicalensis Georgi (Labiatae). Earlier 
studies clearly showed that baicalein has various pharmacological properties such 
as antioxidant, anti-inflammatory, antidiabetic, anticancer, antiulcerative colitis, 
antithrombotic, antiviral, eye protective, cardioprotective, neuroprotective, and 
hepatoprotective properties [25]. It also possesses anticonvulsive, anxiolytic, and 
mild sedative actions [26]. Many studies have clearly demonstrated that baicalein 
protected 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenylpyridinium (MPP+), 
glutamate, amyloid-β (Aβ), hydrogen peroxide (H2O2), 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), and methamphetamine-induced neurotoxicity in 
animal models and cell lines [27–33]. Earlier, some authors clearly reviewed the 
anticancer, anti-inflammatory, cardioprotective properties, ocular disorders, and 
mitochondrial function [34–37]. Li et al. [38] briefed the therapeutic properties of 
baicalein against PD. Baicalein halts PD progression by reducing oxidative stress, 
inhibiting excitotoxicity, inhibiting aggregation of disease-specific amyloid pro-
teins, and stimulating neurogenesis and antiapoptosis as well as anti-inflammatory 
properties. In addition, Gasiorowski et al. [21] reviewed the neuroprotective actions 
of flavones (baicalein, oroxylin A, and wogonin) from the root of S. baicalensis. 
However, scientific literature review on the neuroprotective effects of baicalein is 
still missing.
5. Baicalein inhibits aggregation of α-syn protein
PD develops with the aggregation of disease-specific proteins in amyloid nature. 
Amyloid proteins are predominantly rich in β-sheet fibrillar aggregates composed 
of self-assembly of different proteins including α-syn. Abnormally folded aggre-
gates of α-syn are the key component of Lewy bodies and present as intracellular 
inclusions in nigral dopaminergic neurons in the PD brain [14].
Familial early-onset PD is potentially linked with α-syn mutations [53]. 
Therefore, α-syn is the potential therapeutic target for PD therapy to prevent the 
progression and development of this devastating disease. It is well evidenced that 
preformed α-syn fibrils, oligomeric α-syn, are considered more toxic than mature 
fibrils in arbitrating α-syn-induced neurotoxicity [54, 55]. The underlying mecha-
nism for protein aggregation remains to be elucidated; phytochemicals or molecules 
of natural origin that can halt or slow down the fibrillation process of α-syn 
could be potentially important as new therapeutic strategy for the prevention of 
PD. Remarkably, reports have shown that aggregation of disease-specific α-syn pro-
tein can be inhibited by baicalein. Baicalein, as well as its oxidized forms in lower 
micromolar concentrations, inhibits formation of α-syn fibrils. Moreover, baicalein 
also showed the ability to disaggregate the existing α-syn fibrils [56]. Biophysical 
and experimental (in vitro/in vivo) studies showed that baicalein is capable of 
modifying α-syn aggregation and decreasing the cytotoxicity [57, 58]. In cellular as 
well as cell-free systems, baicalein was found to inhibit the α-syn oligomerization 
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and effectively inhibits α-syn fibrillation. It has been reported that inhibition of 
α-syn oligomer formation was achieved by baicalein treatment in Hela cells and 
SH-SY5Y cells and later was protected from the toxicity induced by α-syn oligomer 
[57]. Further, inhibition of aggregation and cytotoxicity of wild-type α-syn and 
baicalein showed decreased aggregation of different mutant form (E46K A30P and 
A53T) of α-syn in vitro and represented a neuroprotective effect in N2A cellular 
model of familial forms of parkinsonism [58, 59]. Moreover, α-syn aggregation was 
augmented by baicalein in the nigrostriatal dopaminergic system of MPP+-treated 
rat brain [60]. In the intragastrically rotenone-injected chronic mouse model of PD, 
baicalein did not decrease the expression of α-syn mRNA, but significant decrease 
Experimental model 
system
Effects/mechanisms observed References
α-Syn aggregation assay • Inhibits formation of α-syn fibrils
• Disaggregates α-syn fibrils after binding to Tyr residues 
in α-syn
[56]
Dopaminergic cell lines 
(SN4741) overexpressing 
wild-type α-syn or A53T 
mutant-type α-Syn
• Inhibits α-syn fibrillation by covalent binding
• Promotes degradation of α-syn fibrils and polymerization 
to reduce its propagation and transmission
• Enhances cell viability and increases macroautophagy
[76]
Intranigral infusion of 
MPP+ in rat brain
• Attenuates α-syn aggregation
• Inhibits inflammasome activation and cathepsin B 
production
• Inhibits apoptosis (caspases 9 and 12), and autophagy 
(LC3-II)
[60]
α-Syn aggregation in 
infused substantia nigra 
of rats
• S/B formulation containing Scutellaria baicalensis Georgi 
attenuates inflammation, apoptosis, oxidative, mitochon-
drial and ER stress and preserves glutathione
• Attenuates astrocytosis/microgliosis, improves dopamine 
levels
• Inhibits α-syn aggregation in SNc
[77]
PC12 and primary 
dopaminergic neurons
• Dichloromethane and n-butanol extract of Scutellaria 
pinnatifida reduces α-SN aggregation and scavenges free 
radicals
[78]
Biophysical and 
biochemical assays on 39 
polyphenols including 
baicalein
• Inhibits α-syn aggregation [79]
Biophysical and 
biochemical assays on 14 
polyphenols including 
baicalein
• Inhibits α-syn aggregation [80]
Biophysical and 
biochemical assays on 12 
polyphenols including 
baicalein
• Inhibits α-syn aggregation [59]
Biophysical and 
biochemical assays 
on four polyphenols 
including baicalein
• Inhibits α-syn aggregation [81]
Table 1. 
The experimental studies showing the effect of baicalein in PD.
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of α-syn oligomers was observed in the thoracic spinal cord, midbrain, and ileum. 
In the light of this, baicalein could be able to prevent the PD progression through 
inhibiting the aggregation and formation of α-syn oligomers [61]. Although, the 
exact molecular mechanism of baicalein through which inhibition of aggregation 
of α-syn proteins takes place is yet to be elucidated, but characteristic molecular 
structure-based mechanism of baicalein has been proposed. It is well known that 
polyphenols, including baicalein or other flavonoids, are readily oxidized to qui-
nones by oxygen because of their reductive nature, although quinones are readily 
reactive with the side-chain amino groups of proteins. Oxidized form of baicalein, 
that is, baicalein quinones, plays a key role in carrying α-syn inhibitory reactions, 
and the resulting product is mostly soluble α-syn oligomers. In this process, baica-
lein quinone covalently modified the protein molecules to form a Schiff base with 
a lysine side chain in α-syn, and Tyr is involved in the interaction of α-syn with 
baicalein [56]. Moreover, analysis of structure-activity demonstrated that quinone 
formation required vicinal dihydroxyphenyl moieties of baicalein to bind α-syn, 
and for maximum inhibitory effects of baicalein on α-syn fibrillation, three vicinal 
hydroxyl groups are more beneficial compared with two vicinal hydroxyl groups 
[59]. The in vitro inhibitory effects of baicalein on α-syn fibrillation are correlated 
with its antioxidant activities [62]. Recent study showed that non-baicalein-treated 
α-syn oligomers fibrillation can be inhibited by baicalein-stabilized α-syn oligo-
mers. This suggests that some forms of soluble oligomer formation can be beneficial 
because baicalein-stabilized α-syn oligomers do not disrupt the integrity of the 
biological membrane [63]. Hence, these results indicated that baicalein would be a 
therapeutic agent for PD treatment through inhibition of α-syn accumulation and 
aggregation (Table 1).
6. Blood-brain barrier (BBB) penetrating ability
The BBB is an important network that plays a key role in maintaining homeosta-
sis of the central nervous system, and its disturbance is prominently recognized for 
many neuronal disorders [27]. The BBB is made up of microvessel endothelial cells, 
in the arrangement of basement membrane, pericytes, neurons, and astrocytes. The 
BBB brings a hard barrier between the blood and brain parenchyma cells. However, 
several transport systems help to ease the channel of selective constituents across 
the BBB. Tsai et al. [64] reported that baicalein crosses the BBB 20–30 min follow-
ing injection. Wang et al. [65] showed that baicalein remarkably decreased the BBB 
permeability after 24 hours in animal model of subarachnoid hemorrhage.
7. Bioavailability of baicalein
The deprived oral bioavailability and aqueous solubility are the major draw-
back for the pharmaceutical formulations and clinical practice of baicalein. 
Previous reports showed that baicalin and baicalein 6-O-sulfate are the metabolic 
product of baicalein in the blood [66, 67]. Several studies have demonstrated that 
oral administration of baicalein endures widespread glucuronidation within the 
wall of intestine and liver in humans and rats [68]. Additionally, baicalein was 
found less absorbed by colon when compared to stomach and small intestine [69]. 
Lai et al. [70] reported that 75.7% of the baicalein dose injected intravenously was 
found to be circulating in the form of conjugated metabolites in rats. Based on 
the earlier studies, it was documented that intravenous and oral administration 
of baicalein is instantly metabolized into baicalin in the animal’s blood [71, 72]. 
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In another study, conducted on monkeys, it has been reported that the different 
doses of baicalein bioavailability range 23.0 and 13.1% through intravenous and 
oral routes, respectively [73].
8. Clinical trials with baicalein
Baicalein has been shown a novel potential therapeutic agent for the treatment 
of neurological diseases. Therefore, clinical trials are essential for baicalein in order 
to confirm the potential therapeutic efficacy against neurodegenerative diseases. 
Two phase I clinical trials have been done based on chewable tablets of baicalein in 
Chinese healthy adult volunteers.
A phase I (2014), randomized, double-blind test for pharmacokinetic properties 
of baicalein with single-dose trail (100–2800 mg) was investigated on 72 healthy 
Chinese adults [74]. Without any additional treatment, mild adverse effects were 
fixed. Blood pressure and electrocardiogram were found normal during the entire 
period of study. No sign of toxicity observed in liver and kidney or any other serious 
adverse effects were not observed [74].
In 2016, another study in Chinese subjects based on placebo-controlled, 
single-center, and double-blind parallel group investigated the pharmacokinet-
ics, safety, and tolerability of baicalein following multiple-ascending-dose pro-
tocol [75]. Volunteers were randomly divided to get placebo treatment (n = 2 per 
dose regimen) or baicalein (n = 8 per dose regimen). The selected dose regimens 
(200, 400, and 800 mg) were given once daily on days 1 and 10, and twice on 
days 3–9. High-performance liquid chromatography–tandem mass spectrometry 
methods were employed to assay the baicalein and its metabolite in urine, feces, 
and plasma samples. On day 8, plasma samples are given steady-state concentra-
tion of analytes after repeated dosing. The analytes concentration increased with 
increasing dose. The dose proportionality constant (b) for the area under the 
plasma concentration-time curves of baicalein and baicalin was 0.922 (90% con-
fidence interval 0.650–1.195) and 0.942 (90% confidence interval 0.539–1.345), 
respectively.
Phase I clinical trials of baicalein showed that oral administration is safe to 
humans. But additional studies of baicalein are needed in the patients of neurode-
generative diseases to strengthen its therapeutic importance.
9. Conclusion
In the recent years, the pathophysiological understanding of α-syn has 
advanced rapidly from small unfolded protein located into nerve terminals and 
possesses the quality to self-aggregate into fibrils, resembling to Lewy bodies, a 
characteristic pathological hallmark of PD. Moreover, the endpoints of PD are not 
this long structure but an intermediate and transferable agent of the disease and 
is the most potent therapeutic target for PD prevention/treatment. Baicalein has 
showed the neuroprotective effects against PD in both in vitro/in vivo studies. 
Baicalein possesses the antioxidant activity and inhibition of α-syn aggregation. 
This suggests baicalein to be considered as solid treatment tool for neurodegen-
erative diseases including PD. Importantly, baicalein is safe and sufficiently well 
tolerated by healthy volunteers as evidenced by two phase I clinical trials based on 
Chinese healthy adult volunteers [74, 75]. Therefore, the abovementioned proper-
ties of baicalein indicate its potential therapeutic implications in slowing down/
halting the progression of PD.
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